Skip to main content
Top

26-10-2023 | Prostate Cancer | News

ESMO 2023

Added value for combination radium-223 and enzalutamide in mCRPC

MedNet.nl: In the REASSURE study, a combination treatment consisting of radium-223 and enzalutamide appears to have added value for patients with metastatic castration-resistant prostate cancer (mCRPC). A phase 3 trial, the PEACE III trial, is now underway investigating the combination in a randomized setting.

Related topics

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version